David Churchill
Director of Finance/CFO at Brown Advisory, Inc.
David Churchill active positions
Companies | Position | Start | End |
---|---|---|---|
Brown Advisory, Inc.
Brown Advisory, Inc. Financial ConglomeratesFinance Brown Advisory, Inc. provides investment and advisory services. It specializes in investment management, strategic advisory, wealth management, and private equity. The firm provides services to individuals, families, institutions, and corporations. The company was founded in 1993 and is headquartered in Baltimore, MD. | Director/Board Member | - | - |
Director of Finance/CFO | - | - | |
Chief Operating Officer | - | - | |
Brown Advisory Investors 2021- AGL 3 LLLP | Chief Operating Officer | - | - |
Axiom Direct Investors LLC
Axiom Direct Investors LLC Investment ManagersFinance Part of Brown Advisory, Inc., Axiom Direct Investors LLC operates as a private equity fund. The company is based in Baltimore, MD. The CEO of the company is Michael David Hankin. | Chief Operating Officer | - | - |
NextGen Pluto LLC
NextGen Pluto LLC Investment ManagersFinance NextGen Pluto LLC, a special purpose vehicle formed to make investment in Pluto Health Inc. | Director/Board Member | - | - |
PathAI Investors LLC
PathAI Investors LLC Investment ManagersFinance Part of Brown Advisory, Inc., PathAI Investors LLC functions as a private equity fund. The company is based in Baltimore, MD. The CEO of the company is Michael D. Hankin. | Chief Operating Officer | - | - |
Nextgen Sunroom LLC
Nextgen Sunroom LLC Investment ManagersFinance Nextgen Sunroom LLC, a special purpose vehicle formed to make investment in B&Z Homes, Inc. | Director/Board Member | - | - |
Brown Advisory Investors 2021 - VGO LLLP | Chief Operating Officer | - | - |
Brown Advisory Private Equity Partners 10 (A) LLLP | Chief Operating Officer | - | - |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Director/Board Member | 2022-03-21 | - |
░░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Career history of David Churchill
Former positions of David Churchill
Companies | Position | Start | End |
---|---|---|---|
░░░░░ ░░░░░ ░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
Training of David Churchill
Rochester Christian University | Masters Business Admin |
Statistics
International
United States | 15 |
Operational
Director/Board Member | 6 |
Chief Operating Officer | 6 |
Director of Finance/CFO | 2 |
Sectoral
Finance | 12 |
Consumer Services | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 13 |
---|---|
Brown Investment Advisory, Inc.
Brown Investment Advisory, Inc. Investment ManagersFinance Founded in 1993 by J. Dorsey Brown III, Brown Investment Advisory, Inc., also known as Brown Advisory, Inc., is a registered investment advisor headquartered in Baltimore, Maryland. The firm is a wholly-owned subsidiary of Brown Investment Advisory & Trust Co. Brown Investment Advisory provides investment advisory and brokerage services to institutions, corporations and high net-worth individuals and families in the U.S. and abroad. | Finance |
Alex. Brown & Sons, Inc. | Finance |
Brown Advisory, Inc.
Brown Advisory, Inc. Financial ConglomeratesFinance Brown Advisory, Inc. provides investment and advisory services. It specializes in investment management, strategic advisory, wealth management, and private equity. The firm provides services to individuals, families, institutions, and corporations. The company was founded in 1993 and is headquartered in Baltimore, MD. | Finance |
Brown Advisory Investors 2021- AGL 3 LLLP | Finance |
Axiom Direct Investors LLC
Axiom Direct Investors LLC Investment ManagersFinance Part of Brown Advisory, Inc., Axiom Direct Investors LLC operates as a private equity fund. The company is based in Baltimore, MD. The CEO of the company is Michael David Hankin. | Finance |
NextGen Pluto LLC
NextGen Pluto LLC Investment ManagersFinance NextGen Pluto LLC, a special purpose vehicle formed to make investment in Pluto Health Inc. | Finance |
PathAI Investors LLC
PathAI Investors LLC Investment ManagersFinance Part of Brown Advisory, Inc., PathAI Investors LLC functions as a private equity fund. The company is based in Baltimore, MD. The CEO of the company is Michael D. Hankin. | Finance |
Nextgen Sunroom LLC
Nextgen Sunroom LLC Investment ManagersFinance Nextgen Sunroom LLC, a special purpose vehicle formed to make investment in B&Z Homes, Inc. | Finance |
Brown Advisory Investors 2021 - VGO LLLP | Finance |
Brown Advisory Private Equity Partners 10 (A) LLLP | Finance |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Health Technology |
Nextgen Customer Science LLC | |
Nextgen Turtlehealth LLC
Nextgen Turtlehealth LLC Investment ManagersFinance NextGen Turtlehealth LLC a special purpose vehicle, formed to make investment in Turtle Health Inc. | Finance |
- Stock Market
- Insiders
- David Churchill
- Experience